Characteristics of the study population
| . | Study cohort CML patients N = 220 n (%)* . |
|---|---|
| Demographic information | |
| Age (y) | 39.8 ± 9.4 (18-61)† |
| Age groups (no. patients) | |
| 18-30 | 38 (17%) |
| 31-40 | 78 (36%) |
| 41-50 | 74 (34%) |
| > 50 | 30 (14%) |
| Sex (no. patients) | |
| Male | 117 (53%) |
| Female | 103 (47%) |
| Race/Ethnicity (no. patients) | |
| White | 196 (89%) |
| Nonwhite | 24 (11%) |
| Birthplace (no. patients) | |
| United States | 204 (93%) |
| Non-United States | 16 (7%) |
| Weight (kg) | 78.0 ± 15.7 (41.2-132.1)† |
| Height (cm) | 171.2 ± 10.0 (123.4-194.5)† |
| Smoking status (no. patients) | |
| Never | 113 (51%) |
| Current | 9 (4%) |
| Former | 66 (30%) |
| No information | 32 (15%) |
| Transplant-related characteristics | |
| Conditioning regimen (no. patients) | |
| Cy/TBI | 112 (51%) |
| Bu/Cy | 108 (49%) |
| Donor type (no. patients) | |
| Unrelated | 112 (51%) |
| Related | 108 (49%) |
| HLA-matched | 101 (46%) |
| HLA-mismatched | 6 (3%) |
| Unknown | 1 (0.5%) |
| Previous interferon treatment (no. patients) | |
| Yes | 98 (45%) |
| No | 122 (56%) |
| Survival status (no. patients) | |
| Alive | 170 (77%) |
| Dead | 50 (23%) |
| Oral mucositis index | |
| OMI d 6-12 | 20.1 ± 12.2 (0.0-64.0)† |
| OMI d 1-18 | 17.4 ± 9.8 (1.3-54.4)† |
| Granulocyte recovery | |
| Median days to reach 100/μL | 15 (6-38)‡ |
| Median days to reach 500/μL | 21 (11-51)‡ |
| Platelet recovery | |
| Median days to reach 10 000/μL | 18 (9-85)‡ |
| Median days to reach 20 000/μL | 18 (9-85)‡ |
| Bilirubin levels | |
| Median level d 1-18 | 1.42 (0.30-6.64)‡ |
| Highest level d 1-18 | 2.30 (0.50-17.5)‡ |
| Difference between highest and baseline level, d 1-18 | 1.48 (0-17.1)‡ |
| MTHFR genotype (no. patients) | |
| CC (wild type) | 92 (42%) |
| CT (heterozygous) | 92 (42%) |
| TT (homozygous variant) | 36 (16%) |
| . | Study cohort CML patients N = 220 n (%)* . |
|---|---|
| Demographic information | |
| Age (y) | 39.8 ± 9.4 (18-61)† |
| Age groups (no. patients) | |
| 18-30 | 38 (17%) |
| 31-40 | 78 (36%) |
| 41-50 | 74 (34%) |
| > 50 | 30 (14%) |
| Sex (no. patients) | |
| Male | 117 (53%) |
| Female | 103 (47%) |
| Race/Ethnicity (no. patients) | |
| White | 196 (89%) |
| Nonwhite | 24 (11%) |
| Birthplace (no. patients) | |
| United States | 204 (93%) |
| Non-United States | 16 (7%) |
| Weight (kg) | 78.0 ± 15.7 (41.2-132.1)† |
| Height (cm) | 171.2 ± 10.0 (123.4-194.5)† |
| Smoking status (no. patients) | |
| Never | 113 (51%) |
| Current | 9 (4%) |
| Former | 66 (30%) |
| No information | 32 (15%) |
| Transplant-related characteristics | |
| Conditioning regimen (no. patients) | |
| Cy/TBI | 112 (51%) |
| Bu/Cy | 108 (49%) |
| Donor type (no. patients) | |
| Unrelated | 112 (51%) |
| Related | 108 (49%) |
| HLA-matched | 101 (46%) |
| HLA-mismatched | 6 (3%) |
| Unknown | 1 (0.5%) |
| Previous interferon treatment (no. patients) | |
| Yes | 98 (45%) |
| No | 122 (56%) |
| Survival status (no. patients) | |
| Alive | 170 (77%) |
| Dead | 50 (23%) |
| Oral mucositis index | |
| OMI d 6-12 | 20.1 ± 12.2 (0.0-64.0)† |
| OMI d 1-18 | 17.4 ± 9.8 (1.3-54.4)† |
| Granulocyte recovery | |
| Median days to reach 100/μL | 15 (6-38)‡ |
| Median days to reach 500/μL | 21 (11-51)‡ |
| Platelet recovery | |
| Median days to reach 10 000/μL | 18 (9-85)‡ |
| Median days to reach 20 000/μL | 18 (9-85)‡ |
| Bilirubin levels | |
| Median level d 1-18 | 1.42 (0.30-6.64)‡ |
| Highest level d 1-18 | 2.30 (0.50-17.5)‡ |
| Difference between highest and baseline level, d 1-18 | 1.48 (0-17.1)‡ |
| MTHFR genotype (no. patients) | |
| CC (wild type) | 92 (42%) |
| CT (heterozygous) | 92 (42%) |
| TT (homozygous variant) | 36 (16%) |